Table S1. Comparison of HCM patients stratified according to LGE extent

Parameter	All (n=37)	LGE < 5.21 (n=18)	LGE ≥ 5.21 (n=19)	P-value
Age, years, mean, (SD)	50.3 (14.0)	48.7 (14.9)	51.8 (13.4)	0.51
Male sex, n (%)	26 (70.3%)	12 (66.7%)	14 (73.7%)	0.64
BMI, kg/m^2, mean, (SD)	30.3 (5.8)	29.2 (5.2)	31.5 (6.3)	0.23
NYHA class, median (IQR)	1 (1-2)	1 (1-2)	2 (0-2)	0.76
Left ventricular outflow track obstruction, n (%)	11 (29.7%)	8 (44.4%)	3 (15.8%)	0.06
Family history of sudden cardiac death, n (%)	1 (2.7%)	0	1 (5.3%)	1
Ventricular tachycardia, n (%)	13 (35.1%)	3 (16.7%)	10 (52.6%)	0.02
Syncope, n (%)	3 (8.1%)	0	3 (15.8%)	0.23
Diabetes mellutis, n (%)	5 (13.5%)	0	5 (26.3%)	0.046
Coronary artery disease, n (%)	6 (16.2%)	2 (11.1%)	4 (21.1%)	0.66
Hypertension, n (%)	18 (48.6%)	9 (50%)	9 (47.4%)	0.87
Atrial fibrillation, n (%)	5 (13.5%)	1 (5.6%)	4 (21.1%)	0.34
Dyslipidaemia, n (%)	16 (43.2%)	8 (44.4%)	8 (42.1%)	0.89
Estimated 5-year risk of sudden cardiac death, %, median (IQR)	3 (1.9-5)	2.4 (1.5-3.4)	3.9 (2.1-6.3)	0.08
SBP, mmHg, mean, (SD)	130.2 (23.6)	127.9 (20.5)	132.4 (26.6)	0.58
6MWT distance, m, mean, (SD)	427.6 (128.2)	442.5 (129.3)	410.8 (129.1)	0.48
Troponin T, pg/mL, median (IQR)	17 (8-27)	9 (6-17)	21 (17-39)	0.002
NT-proBNP, pg/mL, median (IQR)	481 (202-1117)	460.5 (197-1090)	615 (222-1465)	0.44
PICP, ng/ml, mean, (SD)	299.2 (101.9)	284.7 (66.3)	312.9 (127.3)	0.4
PIIINP, ng/L, median (IQR)	376.2 (328.2-476.8)	392.4 (352-456.6)	371.6 (317.8-693.3)	0.89
Gal-3, ng/ml, mean, (SD)	2.7 (1.29)	2.53 (1.08)	2.86 (1.47)	0.45
TGF-β1, pg/ml, median (IQR)	53.4 (27.3-110.1)	81.1 (22.9-143.6)	44.7 (27.3-84)	0.29
Hb, g/dL, median (IQR)	14.5 (13.6-15.4)	14.6 (14-15.4)	14.3 (13.6-15.4)	0.83
Creatinine, µmol/l, median (IQR)	83 (77.5-93.5)	81 (74-86)	87 (78-94)	0.32
Echocardiographic data:				

Indexed LVEDd, mm/m^2, mean, (SD)	22.4 (3.3)	21.6 (3.7)	23.2 (2.8)	0.16
Max. wall thickness, mm, mean, (SD)	20.4 (4.4)	20.4 (4.3)	20.5 (4.6)	0.95
Left atrium diameter, mm, mean, (SD)	44.3 (6.8)	43.0 (6.7)	45.6 (6.9)	0.25
Left atrial volume index, ml/m², median (IQR)	46.3 (35.2-66.9)	44 (32-65)	47 (35.4-68.8)	0.61
Max. LVOT gradient, mmHg, median (IQR)	20 (8-55)	25.5 (10-82)	13 (8-30)	0.12
E/A, median (IQR)	1.1 (0.8-1.9)	1.03 (0.75-1.76)	1.2 (0.8-2.2)	0.42
E' intraventricular septum, m/s, median (IQR)	0.06 (0.04-0.08)	0.06 (0.05-0.08)	0.06 (0.04-0.08)	0.42
E/E', median (IQR)	11.3 (8-14)	11.8 (6.9-14)	10.1 (8.3-14)	0.9
Right ventricular systolic pressure, mmHg, median (IQR)	23 (16.5-28.5)	27 (15-29)	21 (16.5-26)	0.49
Cardiac magnetic resonance data:				
Indexed LVED volume, ml/m^2, mean, (SD)	81.8 (12.3)	79.6 (13.2)	83.9 (11.3)	0.3
Indexed LVES volume, ml/m^2, median (IQR)	26.9 (20.6-31.8)	23 (19.3-27.8)	30.6 (22.4-32.1)	0.04
Indexed stroke volume, ml/m^2, median (IQR)	54 (44.3-62.5)	54.2 (47.4-64.5)	54.0 (43.1-61.1)	0.38
EF, %, median (IQR)	67 (59-73)	70 (67-73)	63 (48-72)	0.02
Left ventricular mass, grams, mean, (SD)	202.4 (57.8)	208.4 (58.7)	196.3 (58)	0.54
Native T1 time, ms, median (IQR)	1276.1 (1240.3-1325.1)	1259 (1239.4-1289.2)	1306.4 (1240.3-1338.5)	0.16
Post-contrast T1 time, ms, mean, (SD)	460.5 (54)	474.8 (59.1)	447 (46.2)	0.12
Native blood T1 time, ms, median (IQR)	1851.7 (1823.3-1918.7)	1851.3 (1823.3-1888.3)	1854.7 (1804-1963.3)	0.84
Post-contrast blood T1 time, ms, median (IQR)	302 (280-327)	301 (283.3-311.3)	323 (265-336)	0.96
ECV, %, median (IQR)	28.9 (26-31.8)	27.1 (24-30.6)	29.8 (27.3-32.1)	0.11

Pharmacotherapy:				
BB, n (%)	32 (86.5%)	16 (88.9%)	16 (84.2%)	1
Diltiazem/verapamil, n (%)	5 (13.5%)	3 (16.7%)	2 (10.5%)	0.66
ASA, n (%)	6 (16.2%)	3 (16.7%)	3 (15.8 %)	1
ACEi/ARB, n (%)	18 (48.6%)	8 (44.4%)	10 (52.6%)	0.62
MRA, n (%)	12 (32.4%)	4 (22.2%)	8 (42.1%)	0.2
Loop diuretics, n (%)	11 (29.7%)	3 (16.7%)	8 (42.1%)	0.09
Amiodarone, n (%)	2 (5.4%)	2 (11.1%)	0	0.23
OAC, n (%)	5 (13.5%)	1 (5.6%)	4 (21.1%)	0.34
Statins, n (%)	15 (40.5%)	7 (38.9%)	8 (42.1%)	0.84

Abbreviations: ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blockers; ASA, acetylsalicylic acid; BB, beta-blocker; BMI, body mass index; E/A, ratio of early mitral inflow E-wave and late mitral inflow A-wave velocity; ECV, extracellular volume; E/E', ratio of early mitral inflow velocity to early mitral myocardial velocity; EF, left ventricle ejection fraction; Hb, hemoglobin; LGE, late gadolinium enhancement; LVED, left ventricle end-diastolic; LVEDd—left ventricle end-diastolic diameter; LVES, left ventricle end-systolic; LVOT, left ventricular outflow tract; MRA, mineralocorticoid receptor antagonist; NYHA, New York Heart Association class; SBP, systolic blood pressure; OAC, (VKA and non-VKA) oral anticoagulants; 6MWT, 6 min walk test.

Table S2. Univariable regression model for presence of greater LGE extent

	Univariable	
Parameter	**OR (95%CI)**	*P*-value
EF	**0.91 (0.84-0.99)**	**0.03**
Indexed LVES volume	1.08 (0.99-1.19)	0.06
Troponin T	1.06 (0.999-1.12)	0.05

Loop diuretics	3.64 (0.74-17.9)	0.1
Estimated 5-year risk of sudden cardiac death	1.3 (0.96-1.78)	0.08
LVOTO presence	0.23 (0.05-1.16)	0.07
VT presence	**5.56 (1.14-27.16)**	**0.03**

Abbreviations: EF, left ventricle ejection fraction; LVES, left ventricle end-systolic; LVOTO,

left ventricular outflow tract obstruction; VT, ventricular tachycardia